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The ability of Plasmodium falciparum–infected red blood cells (IRBCs) to bind to vascular endothelium, thus enabling
sequestration in vital host organs, is an important pathogenic mechanism in malaria. Adhesion of P. falciparum IRBCs
to platelets, which results in the formation of IRBC clumps, is another cytoadherence phenomenon that is associated
with severe disease. Here, we have used in vitro cytoadherence assays to demonstrate, to our knowledge for the first
time, that P. falciparum IRBCs use the 32-kDa human protein gC1qR/HABP1/p32 as a receptor to bind to human brain
microvascular endothelial cells. In addition, we show that P. falciparum IRBCs can also bind to gC1qR/HABP1/p32 on
platelets to form clumps. Our study has thus identified a novel host receptor that is used for both adhesion to vascular
endothelium and platelet-mediated clumping. Given the association of adhesion to vascular endothelium and platelet-
mediated clumping with severe disease, adhesion to gC1qR/HABP1/p32 by P. falciparum IRBCs may play an important
role in malaria pathogenesis.
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platelet-mediated clumping. PLoS Pathog 3(9): e130. doi:10.1371/journal.ppat.0030130
Introduction
Malaria continues to be a major public health problem in
many parts of the tropical world, with approximately 500
million malaria cases reported annually that result in 1–2
million deaths every year [1,2]. Deaths from malaria mainly
occur in young children living in sub-Saharan Africa and are
caused by infection with P. falciparum. One of the important
virulence mechanisms associated with P. falciparum infection
is the unique ability of P. falciparum trophozoites and
schizonts to sequester in the vasculature of diverse host
organs [3–7]. Sequestration of P. falciparum–infected red
blood cells (IRBCs) in the microvasculature of the brain is
associated with severe pathological outcome of cerebral
malaria [3,5,7]. P. falciparum IRBCs can also bind to platelets
to form platelet-mediated clumps, a cytoadherence phenom-
enon that is associated with severe disease [8–10].
Adhesion of IRBCs to vascular endothelium is mediated by
interaction of the P. falciparum erythrocyte membrane
protein-1 (PfEMP-1) family of variant surface antigens with
host receptors [11–13]. The endothelial receptors used by P.
falciparum for adhesion include thrombospondin (TSP) [14],
CD36 [15], intercellular adhesion molecule-1 (ICAM-1) [16],
platelet/endothelial cell adhesion molecule (PECAM/CD31)
[17], vascular cell adhesion molecule-1 (VCAM-1) [18],
endothelial leukocyte adhesion molecule-1 (ELAM-1) [18],
normal immunoglobulin (IgG) [19], chondroitin sulfate A
(CSA) [20,21], and hyaluronic acid (HA) [22]. Expression of
ICAM-1 is upregulated on cerebrovascular endothelium
[5,23], and P. falciparum IRBCs co-localize with ICAM-1 in
cerebral vessels of patients who die of cerebral malaria [23],
suggesting that adhesion to ICAM-1 plays a key role in
cerebral sequestration. Adhesion of P. falciparum IRBCs to
host vascular endothelium under flow conditions involves
three distinct events, namely, margination, rolling, and static
arrest/tethering, which may require multiple receptor–ligand
interactions [24–26]. Adhesion to endothelial cells under flow
requires binding of P. falciparum IRBCs to ICAM-1 as well as to
CD36 [25]. Expression of ICAM-1 on brain endothelium is
upregulated during blood stage P. falciparum infection [5,23].
However, the expression of CD36 on brain endothelial cells is
minimal [23]. Platelets, which have been shown to accumulate
in brain microvasculature of patients who die of cerebral
malaria, express CD36 on their surface and may act as bridges
for adhesion of P. falciparum IRBCs with brain vascular
endothelium [27–29]. Alternatively, other as yet unidentified
endothelial receptors may play a role in adhesion of P.
falciparum IRBCs to cerebral capillaries. In case of platelet-
mediated clumping, the only receptor identified for binding
of IRBCs to platelets thus far is CD36 [9]. However, in
previous studies, antibodies to CD36 could not completely
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disrupt clumps formed by some P. falciparum field isolates [9],
suggesting that alternative host receptors may participate in
platelet-mediated clumping.
Here, we report the identification of the 32-kDa human
protein gC1qR/HABP1/p32 (referred to below as gC1qR/
HABP1 for brevity) as a novel host receptor for cytoadher-
ence by P. falciparum. gC1qR/HABP1 is a ubiquitously
expressed membrane protein that was initially shown to bind
to the globular ‘‘head’’ of complement component C1q [30] as
well as to HA [31]. This receptor appears to bind to diverse
ligands and has multiple functions [32,33]. It is expressed on
diverse cell types, including endothelial cells [34], platelets
[35], and dendritic cells [36], and is used as a cell surface
receptor by microbial pathogens for pathogenic processes
such as host cell entry [37,38] and suppression of immune
function [39,40]. Given its localization on endothelial cells
and platelets, we hypothesized that gC1qR/HABP1 may serve
as a cytoadherence receptor for P. falciparum.
Here, we demonstrate that gC1qR/HABP1 is expressed on
human brain microvascular endothelial cells (HBMECs) and
can be used by P. falciparum as a receptor for cytoadherence.
In addition, we show that P. falciparum IRBCs can bind gC1qR/
HABP1 on platelets to form platelet-mediated IRBC clumps.
Given the association of both of these cytoadherence
phenotypes with severe malaria, this study identifies a novel
host receptor that may play an important role in malaria
pathogenesis.
Results
Binding of P. falciparum Laboratory Strains and Field
Isolates to Endothelial Receptors gC1qR/HABP1, CD36,
and ICAM-1
Recombinant human gC1qR/HABP1 was expressed in E. coli
and purified to homogeneity (Figure S1). Recombinant
gC1qR/HABP1 has the expected mobility on SDS-PAGE and
has a purity of greater than 98%. Analysis by gel permeation
chromatography reveals that the majority of gC1qR/HABP1 is
trimeric, as predicted by the crystal structure ([41], Figure S1).
Dimers and trimers of gC1qR/HABP1 purified by gel
permeation chromatography migrate with the expected
mobility for gC1qR/HABP1 monomers by SDS-PAGE (Figure
S1). Recombinant gC1qR/HABP1 binds its known ligands,
C1q (Figure S2) and HA (Figure S2), confirming that it is
functional. P. falciparum laboratory strains as well as field
isolates were tested for binding to recombinant gC1qR/
HABP1 coated on plastic Petri plates (Table 1; Figure S3) and
to CD36 and ICAM-1 expressed on the surface of stably
transfected Chinese hamster ovary (CHO) cells (Table 1).
Three of the eight P. falciparum field isolates tested bind
gC1qR/HABP1 (Table 1). Of these, IGH-CR14 shows the most
significant binding to gC1qR/HABP1 (Table 1) and was
selected for further analysis. P. falciparum laboratory strain
3D7, which binds gC1qR/HABP1 (Table 1), was also used for
further study. IGH-CR14 binds CD36 and ICAM-1 in addition
to gC1qR/HABP1, whereas 3D7 binds CD36 and gC1qR/
HABP1 but not ICAM-1 (Table 1). IGH-CR14 binds gC1qR/
HABP1 monomers and trimers at similar levels (Figure S3).
Soluble C1q blocks the binding of IGH-CR14 to gC1qR/
HABP1, suggesting that binding sites on gC1qR/HABP1 used
by IRBCs and C1q may be overlapping (Figure S4). HA has no
effect on binding of IGH-CR14 to gC1qR/HABP1 (Figure S4).
Polymerase chain reaction–based analysis of two polymor-
phic antigens, MSP-1 and MSP-2, using methods described
previously [42] confirmed that both IGH-CR14 and 3D7
contain single distinct genotypes (unpublished data). How-
ever, both IGH-CR14 and 3D7 may contain multiple variants
with distinct binding phenotypes as a result of antigenic
variation. In order to test if P. falciparum IRBCs, which bind
gC1qR/HABP1, can also bind other receptors like CD36 or
ICAM-1, we selected IGH-CR14 and 3D7 for binding to
gC1qR/HABP1, separated binders (IGH-CR14þ and 3D7þ)
from non-binders (IGH-CR14 and 3D7), and tested them in
binding assays. As expected, IGH-CR14þ and 3D7þ show
increased binding to gC1qR/HABP1, whereas IGH-CR14 and
3D7 display reduced binding to gC1qR/HABP1 compared to
IGH-CR14 and 3D7, respectively (Table 2). The gC1qR/
Table 1. Adhesion of P. falciparum Field Isolates and Laboratory
Strains to gC1qR/HABP1, CD36, and ICAM-1
P. falciparum Name gC1qR/
HABP1a
CHO-CD36b CHO-ICAM1b
Field isolates Cal3770 70 22 62
Cal3813 0 107 0
Cal3875 0 20 52
Raj68 0 52 0
Raj86 160 126 5
Raj116 0 7 0
JDP8 0 0 332
IGH-CR14 290 61 15
Laboratory strains A4 20 95 16
ITG-ICAM 0 85 111
3D7 40 47 0
aSpecific binding of P. falciparum IRBCs to gC1qR/HABP1 coated on plastic Petri plates.
Number of IRBCs bound per mm2 is shown. Data represent average of two independent
experiments. Each assay was performed in duplicate in each experiment. Standard error
was less than 10% in each case.
bSpecific binding of P. falciparum IRBCs to CHO-CD36 and CHO-ICAM1 cells. Number of
IRBCs bound per 100 CHO-CD36 or 100 CHO-ICAM1 cells is reported. Data represent
average of two independent experiments. Each assay was performed in duplicate.
Standard error was less than 10% in each case.
doi:10.1371/journal.ppat.0030130.t001
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Author Summary
Adhesion of Plasmodium falciparum–infected red blood cells (IRBCs)
to the endothelium lining the capillaries of vital host organs can
obstruct blood circulation and is an important pathogenic
mechanism in malaria. Adhesion of P. falciparum IRBCs to platelets
results in the formation of IRBC clumps that can also obstruct blood
flow and is implicated in severe malaria. Here, we have identified a
novel cytoadherence receptor that is found on both endothelial cells
and platelets. We demonstrate, for the first time to our knowledge,
that P. falciparum IRBCs use the 32-kDa human protein gC1qR/
HABP1/p32 as a receptor to bind to human endothelial cells,
including brain microvascular endothelial cells. In addition, we show
that P. falciparum IRBCs can bind to gC1qR/HABP1/p32 on platelets
to form clumps. Our study has thus identified a novel host receptor
that is used for both adhesion to vascular endothelium and platelet-
mediated clumping. Given the association of these cytoadherence
phenomena with severe disease, our study opens the door to
investigations on the role of adhesion of P. falciparum IRBCs to
gC1qR/HABP1/p32 in malaria pathogenesis.
HABP1 binders, IGH-CR14þ and 3D7þ, do not bind ICAM-1
or CD36, whereas IGH-CR14 retains binding to ICAM-1 and
CD36, and 3D7 retains binding to CD36 (Table 2). These
findings indicate that binding of P. falciparum IGH-CR14 and
3D7 to gC1qR/HABP1 is not linked to binding to ICAM-1 or
CD36.
Expression of gC1qR on Human Endothelial Cells
We have used mouse serum raised against recombinant
gC1qR/HABP1 to detect gC1qR/HABP1 on the surface of
human umbilical vein endothelial cells (HUVECs), immortal-
ized HBMECs, and primary brain microvascular cells
(PBMECs) by flow cytometry. Anti-gC1qR/HABP1 mouse
serum recognizes a single band of the expected size (32
kDa) in whole cell lysates as well as in membrane preparations
of HUVECs by western blotting (Figure S5). Moreover, anti-
gC1qR/HABP1 mouse serum detects gC1qR/HABP1 on the
surface of HUVECs, HBMECs, and PBMECs by flow cytometry
(Table S1). Unlike ICAM-1, surface expression of gC1qR/
HABP1 is not significantly upregulated on the surface of
HUVECs, HBMECs, and PBMECs following treatment with
TNF-a (Table S1). CD36 is not detected on the surface of
HUVECs, HBMECs, and PBMECs before or after treatment
with TNF-a (Table S1).
P. falciparum IGH-CR14þ and 3D7þUse gC1qR/HABP1 as a
Receptor to Bind Endothelial Cells
In order to explore if P. falciparum IRBCs use gC1qR/HABP1
to bind endothelial cells, we tested IGH-CR14 and 3D7 for
binding to HUVECs and HBMECs. We also tested whether
selection of IGH-CR14 and 3D7 for binding to gC1qR/HABP1
results in enhanced binding to endothelial cells. IGH-CR14þ
and 3D7þ show increased binding to both gC1qR/HABP1 and
HUVECs compared to IGH-CR14 and 3D7 or the non-
binders, IGH-CR14 and 3D7 (Table 2). The association of
enhanced binding to gC1qR/HABP1 and HUVECs (Table 2)
suggested that IGH-CR14þ and 3D7þ use gC1qR/HABP1 as a
cell surface receptor to bind to HUVECs.
In order to confirm that binding of IGH-CR14þ and 3D7þ
to HUVECs was mediated by gC1qR/HABP1, we tested
whether soluble gC1qR/HABP1, as well as anti-gC1qR/HABP1
mouse serum, can inhibit binding of IGH-CR14þ and 3D7þ to
HUVECs. Soluble gC1qR/HABP1 blocks the binding of both
IGH-CR14þ and 3D7þ to HUVECs in a dose-dependent
manner, whereas bovine serum albumin (BSA) and recombi-
nant ICAM1-Fc have no effect on binding (Figure 1). Anti-
gC1qR/HABP1 mouse serum also blocks binding of both IGH-
CR14þ and 3D7þ to HUVECs, whereas pre-immune mouse
serum and antibodies directed against ICAM-1 or CD36 have
no effect on binding (Figure 1). These findings demonstrated
that binding of IGH-CR14þand 3D7þ to HUVECs is mediated
by gC1qR/HABP1.
The gC1qR/HABP1 binder IGH-CR14þ also shows in-
creased binding to HBMECs compared to IGH-CR14 and
IGH-CR14 (Table 2). Binding of IGH-CR14þ to HBMECs is
inhibited by soluble gC1qR/HABP1 but not by ICAM1-Fc or
CD36-Fc (Figure 2). Binding of IGH-CR14þ to HBMECs is also
inhibited by anti-gC1qR/HABP1 mouse serum but not by pre-
immune mouse serum or monoclonal antibodies against
ICAM-1 and CD36 (Figure 2). These findings demonstrate
that IGH-CR14þ uses gC1qR/HABP1 as a receptor to bind to
HBMECs.
P. falciparum IGH-CR14þ and 3D7þUse gC1qR/HABP1 as a
Receptor for Platelet-Mediated Clumping of IRBCs
Mouse serum raised against gC1qR/HABP1 was used to
detect expression of gC1qR/HABP1 on the surface of platelets
by flow cytometry. P-selectin (CD62) was used as a marker for
platelet activation. Whereas gC1qR/HABP1 is detected on the
surface of both resting and activated platelets, P-selectin is
only expressed on the surface of activated platelets (Table S2).
Given the presence of gC1qR/HABP1 on the surface of
platelets, we examined whether P. falciparum could use gC1qR/
HABP1 as a receptor for platelet-mediated IRBC clumping.
IGH-CR14, IGH-CR14þ, and IGH-CR14 were tested for
formation of clumps in the presence of platelet-rich plasma
(PRP) and platelet-poor plasma (PPP). All three parasites
form clumps in the presence of PRP, whereas no clumps are
seen in the presence of PPP (Figure 3). Similarly, 3D7, 3D7þ,
and 3D7 form clumps in the presence of PRP (Figure 3). The
P. falciparum isolate JDP8, which binds ICAM-1 and does not
bind gC1qR/HABP1 or CD36, does not form clumps in PRP or
PPP. IGH-CR14, IGH-CR14, 3D7, and 3D7 bind CD36
(Table 2), which is a known receptor for platelet-mediated
clumping. IGH-CR14þ and 3D7þ do not bind CD36, but bind
gC1qR/HABP1 (Table 2). Analysis of clumps formed by IGH-
CR14þ using scanning and transmission electron microscopy
confirmed the presence of platelets in the clumps (Figure 3),
suggesting that IGH-CR14þ IRBCs use gC1qR/HABP1 as a
receptor to form platelet-mediated clumps.
In order to confirm the identity of the receptor used by
IGH-CR14þ and 3D7þ for platelet-mediated clumping we
tested the ability of soluble gC1qR/HABP1 and CD36-Fc, as
well as antibodies directed against gC1qR/HABP1 and CD36,
to inhibit clumping. Both CD36-Fc and anti-CD36 mono-
clonal antibodies block the clumping of IGH-CR14, IGH-
CR14, 3D7, and 3D7 (Figures 4 and 5). Soluble gC1qR/
Table 2. Adhesion of P. falciparum Isolates to gC1qR/HABP1,
CD36, and ICAM-1, and Endothelial Cell Lines HUVEC and HBMEC
P. falciparuma gC1qR/
HABP1b
CHO-CD36c CHO-ICAM1c HUVECd HBMECe
IGH-CR14 290 61 15 103 26
IGH-CR14þ 1720 0 0 478 98
IGH-CR14 50 71 19 66 11
3D7 40 47 0 18 nd
3D7þ 1790 8 0 202 nd
3D7 0 46 0 6 nd
aP. falciparum field isolate IGH-CR14 and laboratory strain 3D7 were selected three times
on plates coated with gC1qR/HABP1 to separate gC1qR/HABP1 binders (IGH-CR14þ and
3D7þ) from non-binders (IGH-CR14 and 3D7).
bSpecific binding of P. falciparum IRBCs to gC1qR/HABP1 coated on plastic Petri plates.
Number of IRBCs bound per mm2 is reported. Data represent average of two independent
experiments. Each assay was performed in duplicate in each experiment. Standard error
was less than 10% in each case.
cSpecific binding of P. falciparum IRBCs to CHO-CD36 and CHO-ICAM1 cells. Number of
IRBCs bound per 100 CHO-CD36 or 100 CHO-ICAM1 cells is reported. Data represent
average of two independent experiments. Each assay was performed in duplicate in each
experiment. Standard error was less than 10% in each case.
d,eSpecific binding of P. falciparum IRBCs to dHUVECs and eHBMECs. Number of IRBCs
bound per 100 HUVEC or 100 HBMEC cells is reported. Data represent average of two
independent experiments. Each assay was performed in duplicate in each experiment.
Standard error was less than 10% in each case.
nd, not done.
doi:10.1371/journal.ppat.0030130.t002
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HABP1 and anti-gC1qR/HABP1 mouse serum does not
inhibit clumping of these parasites (Figures 4 and 5). These
findings indicate that IGH-CR14, IGH-CR14, 3D7, and 3D7
primarily use CD36 on platelets to form clumps. Conversely,
soluble gC1qR/HABP1 and anti-gC1qR/HABP1 mouse serum
block clumping of IGH-CR14þ and 3D7þ parasites, whereas
CD36-Fc and anti-CD36 monoclonal antibodies do not have
any inhibitory effect on clumping of IGH-CR14þ and 3D7þ
parasites (Figures 4 and 5). These studies confirm that both
IGH-CR14þ and 3D7þ use gC1qR/HABP1 as a receptor for
platelet-mediated clumping.
Discussion
Adhesion of P. falciparum IRBCs to endothelial receptors,
which enables sequestration in host organs, and binding to
Figure 1. Inhibition of IRBCs Binding to HUVECs with Soluble gC1qR/HABP1 and Mouse Antiserum against gC1qR/HABP1
Binding of IRBCs to HUVECs in the presence of soluble proteins is expressed as relative binding compared to binding in absence of any protein (No
protein). Binding in the presence of serum is expressed as relative binding compared to binding in absence of any serum (No sera). Recombinant
gC1qR/HABP1 inhibits binding of IGH-CR14þ (A) and 3D7þ (C) to HUVECs in a dose-dependent manner. Recombinant ICAM-1-Fc and BSA have no effect
on binding of IGH-CR14þ (A) and 3D7þ (C) to HUVECs. Anti-gC1qR/HABP1 mouse serum inhibits binding of IGH-CR14þ (B) and 3D7þ (D) to HUVECs. Pre-
immune mouse serum (PIS), anti-ICAM-1 monoclonal antibody 15.2, and anti-CD36 monoclonal antibody SMU do not have any effect on binding of
IGH-CR14þ (B) and 3D7þ (D) to HUVECs. The number of IRBCs bound per 100 HUVECs was scored in each assay. All data are averages (6 standard error)
derived from two independent experiments. Each assay was performed in duplicate. Binding of IGH-CR14þ and 3D7þ IRBCs in absence of any protein or
serum was in the range of 150–200 IRBCs bound to 100 HUVECs.
doi:10.1371/journal.ppat.0030130.g001
Figure 2. Inhibition of IRBCs Binding to HBMECs with Soluble gC1qR/HABP1 and Mouse Antiserum against gC1qR/HABP1
Binding of IRBCs to HBMECs in the presence of soluble proteins is expressed as relative binding compared to binding in absence of any protein (No
protein). Binding in the presence of serum is expressed as relative binding compared to binding in absence of any serum (No serum). Recombinant gC1qR/
HABP1 inhibits binding of IGH-CR14þ (A) to HBMECs in a dose-dependent manner. Recombinant ICAM-1-Fc, CD36-Fc, and BSA have no effect on binding
of IGH-CR14þ (A). Anti-gC1qR/HABP1 mouse serum inhibits binding of IGH-CR14þ (B) to HBMECs. Pre-immune mouse serum (PIS), anti-ICAM-1 monoclonal
antibody (clone 15.2), and anti-CD36 monoclonal antibody (clone SMU) do not have any effect on binding of IGH-CR14þ (B) to HBMECs. The number of
IRBCs bound to 100 HBMEC cells was scored in each assay. All data are averages (6 standard error) derived from two independent experiments. Each assay
was performed in duplicate. Binding of IGH-CR14þ in absence of any protein or serum was in the range of 90–100 IRBCs bound to 100 HBMECs.
doi:10.1371/journal.ppat.0030130.g002
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platelets, which produces IRBC clumps, are important
pathogenic mechanisms in malaria [4–10]. Here, we report
the identification of the 32-kDa human protein gC1qR/
HABP1 as a novel cytoadherence receptor for adhesion of
P. falciparum IRBCs to both endothelial cells and platelets.
gC1qR/HABP1 is synthesized as a 282–amino acid pre-pro
protein, which contains a 73–amino acid long N-terminal
mitochondrial targeting sequence [43,44]. gC1qR/HABP1 is
found in mitochondria and also on the surface of mammalian
cells. There are other examples of proteins that have
mitochondrial localization sequences and are found in other
cellular locations in addition to mitochondria [45]. For
example, mitochondrial aspartate aminotransferase (ApsAT)
is found in the mitochondria as well as on the plasma
membrane of adipocytes, where it is involved in binding and
uptake of fatty acids [45]. Another mammalian protein, Slit3,
whose homolog in Drosophila is involved in developmental
regulation, is predominantly a mitochondrial protein having
an N-terminal mitochondrial targeting sequence, but is also
shown to be expressed on epithelial cell surfaces [46]. The
mechanisms by which these proteins translocate to the cell
surface and to the mitochondria are not known. Given the
presence of the mitochondrial targeting sequence and
absence of a transmembrane domain or consensus glcophos-
phatidyl inositol (GPI)–anchoring signature sequence, the
surface localization of gC1qR/HABP1 is intriguing. The
localization of gC1qR/HABP1 on the surface of diverse
human cells has been demonstrated unequivocally both here
and previously [31–34,47,48]. We have demonstrated here
that mouse serum raised against recombinant gC1qR/HABP1
specifically reacts with a protein of the expected size for
gC1qR/HABP1 (32 kDa) in whole cell lysates as well as in
membrane fractions of HUVECs by western blotting (Figure
S5). Anti-gC1qR/HABP1 mouse serum detects the presence of
gC1qR/HABP1 on the surface of HUVECs, HBMECs, and
PBMECs by flow cytometry (Table S1). The observation that
gC1qR/HABP1 is expressed on the surface of microvascular
endothelial cells suggests the possibility that it may be used as
Figure 3. Platelet-Mediated Clumping of P. falciparum IRBCs
(A) Frequency of platelet-mediated clumping in PRP and PPP. P. falciparum field isolate IGH-CR14, laboratory strain 3D7, and their derivatives, IGH-
CR14þ and 3D7þ, which bind gC1qR/HABP1, IGH-CR14, and 3D7, which bind CD36, and P. falciparum isolate JDP8, which does not bind gC1qR/
HABP1 or CD36, were tested for clumping in the presence of PRP and PPP. Parasites in trophozoite and schizont stages were allowed to form clumps in
the presence of PRP and PPP. Parasites were stained with acridine orange and the clumping frequency was determined by scoring the frequency of
IRBCs found in clumps. Approximately 500 IRBCs were scored for each parasite. The frequency of clumping in the presence of PRP (grey bars) and PPP
(black bars) is shown.
(B) Scanning electron micrograph of platelet-mediated clumps formed by IGH-CR14þ. Clumps formed by IGH-CR14þ IRBCs in the presence of PRP were
analyzed by scanning electron microscopy. Electron micrograph shows several platelets (marked P), which bridge IRBCs in the clumps.
(C) Transmission electron micrograph of platelet-mediated clumps formed by IGH-CR14þ. Clumps formed by IGH-CR14þ IRBCs in the presence of PRP
were analyzed by transmission electron microscopy. Only IRBCs are present in the clumps. The IRBCs are closely associated with platelets (P) in the
clumps.
doi:10.1371/journal.ppat.0030130.g003
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a receptor for cytoadherence by P. falciparum IRBCs. Given
that the expression profile of the cytoadherence receptors
gC1qR/HABP1, ICAM-1, and CD36 on HUVECs, HBMECs,
and PBMECs is similar, we used HUVECs and HBMECs for
adhesion assays with P. falciparum IRBCs.
We have demonstrated that P. falciparum laboratory strains
as well as field isolates can bind to recombinant gC1qR/
HABP1 (Table 1; Figure S3). Selection of P. falciparum IGH-
CR14 and 3D7 for binding to gC1qR/HABP1 allowed
separation of gC1qR/HABP1 binders IGH-CR14þ and 3D7þ,
and non-binders IGH-CR14 and 3D7. Selection of IGH-
CR14 and 3D7 for binding to gC1qR/HABP1 resulted in
increased binding of IRBCs to HUVECs and HBMECs (Table
2), suggesting that these parasites use gC1qR/HABP1 to bind
to human endothelial cells. Indeed, recombinant gC1qR/
HABP1, as well as anti-gC1qR/HABP1 mouse serum, blocked
the binding of IGH-CR14þ to HUVECs and HBMECs (Figures
1 and 2), confirming that these parasites use gC1qR/HABP1 as
a receptor for adhesion of IRBCs to endothelial cells. The
demonstration that P. falciparum IRBCs can use gC1qR/
HABP1 as a receptor to bind to microvascular endothelial
Figure 4. Inhibition of Platelet-Mediated Clumping of IRBCs by Soluble gC1qR/HABP1 and CD36-Fc
Parasite cultures in trophozoite and schizont stages were allowed to form clumps in the presence of PRP. Parasites were stained with acridine orange
and the clumping frequency was determined by scoring the frequency of IRBCs found in clumps. Approximately 2,000 to 3,000 IRBCs were scored.
Parasite cultures were pre-incubated with recombinant gC1qR/HABP1 or CD36-Fc at different concentrations prior to use in clumping assays to test
their ability to inhibit clumping. Clumping frequency in the presence of gC1qR/HABP1 or CD36-Fc is expressed as relative clumping compared to
clumping in the presence of PRP alone. Data represent the average (6 standard error) of two independent experiments. Each assay was performed in
duplicate. (A) IGH-CR14, (B) 3D7, (C) IGH-CR14, (D) 3D7, (E) IGH-CR14þ, (F) 3D7þ.
doi:10.1371/journal.ppat.0030130.g004
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cells suggests that adhesion to gC1qR/HABP1 may play a role
in parasite sequestration in vivo.
Another distinct cytoadherence phenotype that is associ-
ated with severe malaria is platelet-mediated clumping of
IRBCs. CD36, which is expressed on both resting and
activated platelets, has been identified as a receptor for
platelet-mediated clumping [9]. However, in a previous study,
clumps formed by some P. falciparum field isolates could not
be disrupted completely by anti-CD36 antibodies [9], suggest-
ing that other unidentified receptors on platelets might also
mediate clumping of IRBCs. Previous studies have suggested
that gC1qR/HABP1 is expressed on the surface of activated
platelets [35]. Here, we have demonstrated that gC1qR/
HABP1 is also expressed on resting platelets (Table S2).
Expression of gC1qR/HABP1 on the surface increases upon
activation of platelets (Table S2). IGH-CR14þ and 3D7þ,
which bind to gC1qR/HABP1 but not to CD36, formed
clumps in the presence of platelets. Formation of clumps by
IGH-CR14þand 3D7þwas inhibited by soluble gC1qR/HABP1
and anti-gC1qR/HABP1 antibodies (Figures 4 and 5). These
observations demonstrate that P. falciparum IRBCs can use
gC1qR/HABP1 as an alternative receptor to bind to platelets
and form clumps.
The parasite ligands that mediate adhesion of IRBCs to
gC1qR/HABP1 remain to be identified. Previous studies have
demonstrated that the PfEMP-1 family of variant surface
antigens encoded by var genes mediates interactions with a
diverse range of host receptors to enable adhesion to host
endothelium and sequestration in host organs [4,6,12,13]. It is
likely that PfEMP-1 may also mediate adhesion to gC1qR/
HABP1. Identification of var genes that are differentially
transcribed in gC1qR/HABP1 binding parasites may enable
the identification of the PfEMP-1 variant that is responsible
for adhesion to gC1qR/HABP1.
In summary, we have shown that P. falciparum IRBCs use
gC1qR/HABP1 as a receptor to bind vascular endothelium
and platelets. The observation that P. falciparum can use
gC1qR/HABP1 as a receptor to bind HBMECs, a cell line
derived from brain microvascular endothelial cells, raises the
possibility that adhesion of IRBCs to this novel receptor may
be important for sequestration in brain microvasculature and
cerebral malaria. The contribution of IRBC adhesion to
Figure 5. Inhibition of Platelet-Mediated Clumping of IRBCs by Mouse Serum Directed against gC1qR/HABP1 and Monoclonal Antibody against CD36
Parasite cultures in trophozoite and schizont stages were allowed to form clumps in the presence of PRP. Parasites were stained with acridine orange
and the clumping frequency was determined by scoring the percentage of IRBCs found in clumps. Approximately 2,000 to 3,000 IRBCs were scored. The
ability of anti-gC1qR/HABP1 mouse serum (anti-gC1qR/HABP1) or anti-CD36 mouse monoclonal IgM antibody (anti-CD36, clone SMU) to inhibit clump
formation was tested by pre-incubating platelets with antibodies prior to use in clumping assays. Pre-immune serum (PIS) from mice immunized with
gC1qR/HABP1 and purified mouse IgM were used as controls. Clumping frequency in the presence of anti-gC1qR/HABP1 or anti-CD36 is expressed
relative to clumping in the presence of PRP alone. Data represent average (6 standard error) of two independent experiments. Each assay was
performed in duplicate. (A) IGH-CR14, (B) 3D7, (C) IGH-CR14, (D) 3D7, (E) IGH-CR14þ, (F) 3D7þ.
doi:10.1371/journal.ppat.0030130.g005
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gC1qR/HABP1 to platelet-mediated clumping and severe
disease also needs to be examined. Comparison of the
cytoadherence phenotypes of P. falciparum isolates collected
from patients with mild and severe malaria may allow us to
test whether adhesion to gC1qR/HABP1 is associated with an
increased risk of severe malaria.
Materials and Methods
Materials. All chemicals used in the study were from Sigma (http://
www.sigmaaldrich.com/) unless otherwise indicated.
Parasites. Indian P. falciparum field isolates were collected from P.
falciparum–infected individuals in Calcutta (Cal3770, Cal3813,
Cal3875), Rajasthan (Raj68, Raj86, Raj116), Jagdalpur, Madhya
Pradesh (JDP8), and Rourkela, Orissa (IGH-CR14), and cryopreserved
in the Malaria Parasite Bank at the National Institute of Malaria
Research, Delhi, India. P. falciparum field isolates and laboratory
strains (A4, ITG-ICAM, and 3D7) were cultured in RPMI 1640
(Invitrogen, http://www.invitrogen.com/) supplemented either with
10% heat-inactivated Oþ pooled human sera or 5% Albumax I
(Invitrogen) using Oþ RBCs in an environment containing 5% O2,
5% CO2, and 90% N2. Cultures were synchronized by sorbitol
treatment as previously described [49]. To select parasites for binding
to gC1qR/HABP1, synchronized P. falciparum 3D7 and IGH-CR14
cultures in trophozoite/schizont stages were incubated for 1 h in
bacteriological Petri plates coated with recombinant gC1qR/HABP1
as described below for adhesion assays. Unbound parasites were
collected using a pipette and separated from bound parasites. Both
bound and unbound parasites were cultured and subjected to
selection for binding to gC1qR/HABP1 two more times to separate
binders (3D7þ and IGH-CR14þ) and non-binders (3D7 and IGH-
CR14).
Cell lines. Glycosaminoglycan biosynthesis–defective mutant Chi-
nese hamster ovary cells (CHO-745) stably transfected to express
human CD36 (CHO-CD36) and ICAM-1 (CHO-ICAM-1) on their
surface [50] were kindly provided by Artur Scherf, Institut Pasteur,
Paris, France. CHO cells were cultured in RPMI 1640 with 10% heat-
inactivated fetal bovine serum (FBS). HUVECs were cultured in EBM2
bullet kit media (Cambrex Biosciences, http://www.cambrex.com/) on
gelatin-coated flasks according to instructions provided by the
supplier. Immortalized HBMECs were cultured as previously
described [51]. PBMECs were cultured in EGM-2 media provided by
the supplier (ScienCell Research Laboratories, http://www.
sciencellonline.com/).
Purification and characterization of recombinant human gC1qR/
HABP1. A DNA fragment encoding mature human gC1qR/HABP1
(amino acids 74–282) was cloned in pET30b vector (Invitrogen) using
the NdeI and BamHI restriction enzyme cloning sites. Recombinant
gC1qR/HABP1 was expressed in E. coli BL21(DE3) by induction with
isopropyl-1-thio-b-galactosidase (IPTG) and purified from super-
natants of lysed cells by ammonium sulfate fractionation followed by
ion-exchange chromatography using UnoQ (Bio-Rad, http://www.
bio-rad.com/) as described previously [39]. Binding of recombinant
gC1qR/HABP1 to its ligands, C1q and HA, was tested in solid phase
binding assays as follows. gC1qR/HABP1 and HA were biotinylated
with sulfo-NHS-LC-biotin and biotin-LC-hydrazide, respectively, as
described by the manufacturer (Pierce Biotechnology, http://www.
piercenet.com/). Ninety-six-well plates were coated at 4 8C overnight
with human C1q (250 ng per well). After blocking with 2% non-fat
milk, the wells were incubated with varying concentrations of
biotinylated gC1qR/HABP1. Bound biotin-gC1qR/HABP1 was de-
tected with streptavidin-horse radish peroxidase (HRPO) using o-
phenylene diamine dihydrochloride (OPD) as substrate. In order to
test the binding of gC1qR/HABP1 to HA, ELISA plate wells were
coated with recombinant gC1qR/HABP1 (250 ng per well) and
incubated with different concentrations of biotin-HA. Bound
biotin-HA was detected using streptavidin-HRPO and OPD.
Adhesion assays with soluble proteins and stable CHO cell
transfectants. Ten microliters of purified gC1qR/HABP1 (100 lg/ml)
was spotted on bacteriological Petri plates (Becton Dickinson, http://
www.bd.com/), allowed to adsorb overnight at 4 8C in a humidified
chamber and used for binding assays with parasite cultures as
previously described for binding to soluble CD36 and ICAM-1 [52].
BSA was spotted as control. Trophozoite-schizont stage parasite
cultures at ;1% hematocrit and ;5% parasitemia were incubated
with gC1qR/HABP1-coated Petri plates to allow binding. Bound cells
were fixed with 2% glutaraldehyde, stained with 5% Giemsa stain,
and scored using a Nikon TE200 microscope with a 1003 objective.
The total number of IRBCs and uninfected RBCs (URBCs) were
counted from seven randomly selected distinct fields in duplicate
spots from two independent experiments. The number of URBCs
bound to gC1qR/HABP1 and the number of IRBCs bound to BSA
spots was subtracted from the number of IRBCs bound to gC1qR/
HABP1 to get the number of specific binding events. Fewer than five
URBCs bound gC1qR/HABP1 per mm2, and fewer than five IRBCs
bound BSA per mm2.
CHO-745, CHO-CD36, and CHO-ICAM1 cells were grown in spots
in tissue culture plates and tested for binding to P. falciparum
trophozoite-schizont stage cultures using methods described earlier
[52]. Bound IRBCs were fixed with 2% glutaraldehyde and detected
by Giemsa staining. The number of IRBCs and URBCs bound to;200
CHO cells was scored in duplicate spots in two independent
experiments. The number of URBCs bound to CHO-CD36 or CHO-
ICAM1 was subtracted from bound IRBCs in each case. The number
of IRBCs bound to CHO-745 was further subtracted from the number
of IRBCs bound to CHO-CD36 and CHO-ICAM1 to obtain the
number of specific binding events. Fewer than three URBCs bound to
100 CHO-CD36 or CHO-ICAM1 cells, and fewer than two IRBCs
bound to 100 CHO-745 cells in all experiments. Specific binding of
ten IRBCs or more per 100 CHO-ICAM1 or CHO-CD36 cell was
therefore considered significant.
Flow cytometry. Flow cytometry was used to study the expression
of gC1qR/HABP1, ICAM-1, and CD36 on the surface of HUVECs,
HBMECs, and PBMECs before and after treatment with TNF-a
(eBioscience, http://www.ebioscience.com/) and on the surface of
resting and activated platelets.
HUVECs, HBMECs, and PBMECs were cultured as described above
and were treated with TNF-a (15 ng/ml) for 24 h before analysis.
Mouse serum raised against gC1qR/HABP1 (diluted 1:100), anti-
ICAM-1 monoclonal antibody 15.2 (1 lg per 106 cells; Serotec, http://
www.serotec.co.uk/), and anti-CD36 monoclonal antibody SMU (1 lg
per 106 cells, Serotec) were used for detection of receptors by flow
cytometry using the BD FACSCalibur System (Becton Dickinson).
Resting platelets were isolated from whole blood collected in
citrate-phosphate-dextrose (CPD) as follows. PRP was separated by
centrifugation of whole blood at 300g for 5 min at room temperature
(RT). PRP was incubated in equal volume of CCAT buffer (7.7 mM
citric acid, 95 mM trisodium citrate, 150 mM glucose, 5 mM
adenosine, 3 mM theophylline) for 10 min at RT. Platelets were
collected by centrifugation of PRP at 1,000g for 10 min at RT, washed
once in CCAT buffer and resuspended in modified Hank’s balanced
salt buffer (136 mM NaCl, 5.3 mM KCl, 0.4 mM MgSO4.7H2O, 0.3 mM
NaH2PO4.2H2O, 0.77 mM Na2HPO4, 0.44 mM KH2PO4, 0.5 mM
MgCl2.6H2O, 5.5 mM glucose, 0.4 mM NaHCO3), and stored at RT
until use. Resting platelets resuspended in RPMI 1640 were activated
by treatment with thrombin (100 units/ml; Sigma Chemicals, http://
www.sigmaaldrich.com/) for 30 min at 37 8C. Resting and activated
platelets were fixed with 2% p-formaldehyde and 0.2% glutaralde-
hyde in phosphate buffered saline for 30 min at 4 8C. Mouse
antiserum raised against gC1qR/HABP1 (diluted 1:100) and anti-P-
selectin monoclonal IgG antibody CTB201 (1 lg per 106 platelets;
Santa Cruz Biotechnology, http://www.scbt.com/) were used for
detection of receptors by flow cytometry using the BD FACSCalibur
System (Becton Dickinson).
Binding assay with endothelial cells and inhibition with soluble
proteins and sera. HUVECs and HBMECs were grown on gelatin-
coated plates and used for binding assays with IRBCs following the
same procedure used in case of CHO-CD36 and CHO-ICAM1 cells
described above. For inhibition assays, either parasite cultures were
pre-incubated with ICAM1-Fc (R&D Systems, http://www.rndsystems.
com/), gC1qR/HABP1, and BSA, or HUVECs were pre-incubated with
anti-gC1qR/HABP1 mouse serum or monoclonal antibodies directed
against CD36 (clone SMU, Serotec) and ICAM-1 (clone 15.2, Serotec).
Binding in the presence of proteins or serum was expressed as
percent of binding in absence of any protein or serum.
Platelet-mediated clumping assay and inhibition of clumping with
soluble proteins and sera. Platelet-mediated clumping assays were
performed in the presence of PRP and PPP according to the method
described previously [9]. IRBCs were labeled with acridine orange and
the percentage of IRBCs present in clumps was determined by
scoring ;3,000 IRBCs at 203 magnification using a fluorescence
microscope to determine frequency of clumping. A clump consists of
three or more IRBCs as described previously [9]. All the clumps
observed had fewer than 50 IRBCs. Parasite cultures were pre-
incubated with soluble gC1qR/HABP1 or CD36-Fc (R&D Systems) for
10 min prior to adding PRP to test their ability to inhibit clumping.
Antibodies directed against host proteins were added to PRP prior to
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e1301278
gC1qR/HABP1, P. falciparum Adhesion Receptor
incubation with parasite cultures to test their ability to block
clumping.
Electron microscopy. Cells were fixed in 2.5% glutaraldehyde in 0.1
M phosphate buffer (pH 7.2) and processed according to methods
described previously [9]. Samples were analyzed on a Morgagni 268D
transmission electron microscope (FEI Philips, http://www.fei.com/)
and LEO 435 VP scanning electron microscope (Leo Electron
Microscopy, http://www.smt.zeiss.com/nts).
Supporting Information
Figure S1. Characterization of Recombinant Human gC1qR/HABP1
(A) Purity of recombinant gC1qR/HABP1. Purified gC1qR/HABP1 was
analyzed by SDS-PAGE under reducing conditions and detected by
Coomassie staining. Different amounts of BSA (0.1 lg, 0.2 lg, 0.5 lg,
and 1.0 lg) were used as control. Molecular weight markers are shown
in kDa. (B) Recombinant gC1qR/HABP1 forms trimers. Recombinant
purified gC1qR/HABP1 was analyzed by gel permeation chromatog-
raphy using Superdex 200 HR10/30 column. Theoretical molecular
mass of gC1qR/HABP1 is 23 kDa. Recombinant gC1qR/HABP1
primarily migrates as a trimer with molecular weight of ;69 kDa.
Blue dextran 2000 (2,000 kDa), BSA (67 kDa), ovalbumin (43 kDa), and
ribonuclease A (13.7 kDa) were used as molecular weight standards
for gel filtration chromatography. Majority of gC1qR/HABP1 forms
trimers (C) SDS-PAGE analysis of recombinant gC1qR/HABP1.
Monomers, dimers, and trimers of recombinant gC1qR/HABP1 were
purified by gel permeation chromatography and analyzed by SDS-
PAGE before and after reduction with bmecaptoethanol (b-ME).
Molecular weights are shown in kDa.
Found at doi:10.1371/journal.ppat.0030130.sg001 (295 KB PDF).
Figure S2. Functional Characterization of Recombinant gC1qR/
HABP1
(A) Binding of recombinant gC1qR/HABP1 to C1q. Biotinylated
recombinant gC1qR/HABP1 specifically binds wells coated with
human C1q. (B) Binding of recombinant gC1qR/HABP1 to HA.
Biotinylated HA specifically binds to wells coated with recombinant
gC1qR/HABP1. Binding to BSA-coated wells was used as control (a
and B).
Found at doi:10.1371/journal.ppat.0030130.sg002 (206 KB PDF).
Figure S3. Binding of P. falciparum IRBCs to Purified gC1qR/HABP1
(A) Binding of IRBCs to gC1qR/HABP1 coated on plastic Petri plates.
Giemsa-stained P. falciparum IGH-CR14 IRBCs are seen bound to
recombinant gC1qR/HABP1 coated on plastic Petri plates. (B)
Concentration-dependent binding of IRBCs to gC1qR/HABP1.
Binding of P. falciparum IGH-CR14 IRBCs to gC1qR/HABP1 coated
at various concentrations on plastic Petri plates. Data presented are
average number of IRBCs bound per mm2 (6 standard error) scored
in duplicate spots in two independent experiments. (C) Binding of
IRBCs to monomeric and trimeric gC1qR/HABP1. Binding of P.
falciparum IGH-CR14 to gC1qR/HABP1 monomers and trimers
purified by gel permeation chromatography is shown relative to
binding to gC1qR/HABP1 containing mixed population (Mix) of
monomers, dimers, and trimers. Average relative binding (6 stand-
ard error) scored in duplicate spots in two independent experiments
is reported.
Found at doi:10.1371/journal.ppat.0030130.sg003 (764 KB PDF).
Figure S4. Binding of P. falciparum IGH-CR14 to gC1qR/HABP1 in the
Presence of C1q and HA
(A) Binding of P. falciparum IGH-CR14 to gC1qR/HABP1 and CD36-Fc
in the presence of soluble C1q is expressed as relative binding
compared to binding in absence of C1q. C1q blocks binding of IGH-
CR14 to gC1qR/HABP1 but does not block binding of IGH-CR14 to
CD36-Fc. (B) Binding of P. falciparum IGH-CR14 to gC1qR/HABP1 in
the presence of HA (1 mg/ml) is expressed as relative binding
compared to binding in absence of HA. Average relative binding (6
standard error) scored in duplicate spots in two independent
experiments is reported.
Found at doi:10.1371/journal.ppat.0030130.sg004 (239 KB PDF).
Figure S5. Detection of gC1qR/HABP1 in HUVEC Cells by Western
Blotting
Western blotting with anti-gC1qR mouse serum (A) and anti-bcl2
rabbit serum (B). HUVEC cells were lysed by multiple cycles of
freezing and thawing. Whole cell lysate (L), soluble cytoplasmic
fraction (C), and insoluble membrane fraction (M) were separated by
SDS-PAGE and probed for presence of gC1qR/HABP by western
blotting with anti-gC1qR/HABP1 mouse serum. Recombinant gC1qR/
HABP1 (rH) was used as a positive control. In a control experiment,
rabbit serum raised against the mitochondrial protein, bcl-2, was used
to detect any mitochondrial contamination in the membrane
fraction. Anti-gC1qR mouse serum detects a protein of the expected
size (32 kDa) in all three fractions, including membrane fraction.
Anti-bcl2 rabbit serum only detects protein in whole cell lysate and
cytosolic fractions.
Found at doi:10.1371/journal.ppat.0030130.sg005 (788 KB PDF).
Table S1. Detection of gC1qR/HABP1, ICAM-1, and CD36 on
HUVECs, HBMECs, and PBMECs Before and After Treatment with
TNF-a by Flow Cytometry
Found at doi:10.1371/journal.ppat.0030130.st001 (37 KB RTF).
Table S2. Detection of gC1qR/HABP1 and P-Selectin on Resting and
Thrombin-Activated Platelets by Flow Cytometry
Found at doi:10.1371/journal.ppat.0030130.st002 (18 KB RTF).
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